In the latest trading session, 2.1 million Monopar Therapeutics Inc (NASDAQ:MNPR) shares changed hands as the company’s beta touched 1.18. With the company’s most recent per share price at $2.35 changed hands at -$0.13 or -5.24% at last look, the market valuation stands at $8.27M. MNPR’s current price is a discount, trading about -268.09% off its 52-week high of $8.65. The share price had its 52-week low at $1.37, which suggests the last value was 41.7% up since then. When we look at Monopar Therapeutics Inc’s average trading volume, we note the 10-day average is 39864.0 shares, with the 3-month average coming to 26.62K.
Analysts gave the Monopar Therapeutics Inc (MNPR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended MNPR as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Monopar Therapeutics Inc’s EPS for the current quarter is expected to be -0.48.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Monopar Therapeutics Inc (NASDAQ:MNPR) trade information
Instantly MNPR was in red as seen in intraday trades today. With action 3.07%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 38.15%, with the 5-day performance at 3.07% in the green. However, in the 30-day time frame, Monopar Therapeutics Inc (NASDAQ:MNPR) is -26.56% down. Looking at the short shares, we see there were 17962.0 shares sold at short interest cover period of 1.63 days.
Monopar Therapeutics Inc (MNPR) estimates and forecasts
Data shows that the Monopar Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -17.54% over the past 6 months, a 36.72% in annual growth rate that is considerably higher than the industry average of 18.50%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -14.80%. The 2024 estimates are for Monopar Therapeutics Inc earnings to decrease by -140.44%.
MNPR Dividends
Monopar Therapeutics Inc is expected to release its next quarterly earnings report on 2024-Nov-07.
Monopar Therapeutics Inc (NASDAQ:MNPR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 53.29% of Monopar Therapeutics Inc shares while 2.38% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 5.09%. There are 2.38% institutions holding the Monopar Therapeutics Inc stock share, with MILLENNIUM MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 1.2159% of the shares, roughly 0.19 million MNPR shares worth $0.15 million.
GEODE CAPITAL MANAGEMENT, LLC holds the second largest percentage of outstanding shares, with 0.3757% or 60036.0 shares worth $44906.0 as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2024 were Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund. With 9.03 shares estimated at $21317.0 under it, the former controlled 0.05% of total outstanding shares. On the other hand, Fidelity Extended Market Index Fund held about 0.05% of the shares, roughly 8.31 shares worth around $19602.0.
